Skip to content
    MCK
    Earnings call· Mar 2026(Q4 FY26)

    MCKESSON Q4 FY26 earnings call MCK

    May 7, 2026 Source

    Executive summary

    McKesson Q4 FY26 — Strong Performance and Strategic Portfolio Actions Drive Growth

    McKesson delivered a strong Q4 and full fiscal year 2026, driven by robust performance across its strategic growth platforms and disciplined portfolio optimization, including significant progress on the Medical Surgical Solutions separation. The company is well-positioned for fiscal 2027, reaffirming long-term growth targets and focusing on operational excellence, technology investments, and continued capital returns to shareholders.

    Highlights

    5

    • Adjusted earnings per diluted share grew 18% in fiscal 2026 to $39.11.

    • Operating cash flow was strong at $6.2 billion for fiscal 2026, exceeding plans.

    • Returned $5.1 billion to shareholders in fiscal 2026 through share repurchases and dividends.

    • U.S. Oncology network added over 570 providers in fiscal 2026, the largest net increase since 2010.

    • Biopharma services supported a record 3.4 million patients, helping them save approximately $10 billion on medications.

    Concerns

    3

    • Branded pharmaceutical price changes related to the Inflation Reduction Act reduced Q4 FY26 revenue growth by approximately 3%.

    • GLP-1 distribution revenues declined 4% sequentially in Q4 FY26, though still up 22% year-over-year.

    • Medical Surgical Solutions operating profit decreased 5% in Q4 FY26 due to lower illness season product demand.

    Guidance & targets

    22
    CategoryTargetConfidence
    Adjusted earnings per diluted share
    $43.80 to $44.60
    high materiality
    High
    Long-term adjusted earnings per diluted share growth
    13% to 16%
    high materiality
    High
    Long-term North American Pharmaceutical adjusted segment operating profit growth
    5% to 8%
    medium materiality
    High
    Long-term Oncology and Multi-specialty adjusted segment operating profit growth
    13% to 16%
    medium materiality
    High
    Long-term Prescription Technology Solutions adjusted segment operating profit growth
    10% to 13%
    medium materiality
    High
    North American Pharmaceutical revenue growth
    4% to 8%
    medium materiality
    High
    North American Pharmaceutical operating profit growth
    5.5% to 9.5%
    medium materiality
    High
    Oncology and Multispecialty revenue growth
    14.5% to 18.5%
    medium materiality
    High
    Oncology and Multispecialty operating profit growth
    13.5% to 17.5%
    medium materiality
    High
    Prescription Technology Solutions revenue growth
    2.5% to 6.5%
    medium materiality
    Medium
    Prescription Technology Solutions operating profit growth
    11% to 15%
    medium materiality
    High
    Medical Surgical Solutions revenue growth
    1% to 6%
    medium materiality
    Medium
    Medical Surgical Solutions operating profit growth
    flat to 4%
    medium materiality
    Medium
    Corporate expenses
    $580 million to $640 million
    low materiality
    High
    Interest expense
    $380 million to $420 million
    low materiality
    High
    Income attributable to noncontrolling interest
    $295 million to $325 million
    low materiality
    High
    Full year effective tax rate
    17% to 19%
    low materiality
    High
    Free cash flow
    $4.5 billion to $4.9 billion
    high materiality
    High
    Share repurchases
    approximately $5 billion
    high materiality
    High
    Weighted average diluted shares outstanding
    116 million to 118 million
    low materiality
    High
    Consolidated revenue growth
    5% to 9%
    high materiality
    High
    Adjusted operating profit growth
    8% to 12%
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    North American Pharmaceutical
    Driven by higher prescription volumes, including continued strength in Specialty Products, partially offset by lower branded pharmaceutical revenue due to declines in manufactured prices (reduced YoY revenue growth by ~3%).
    Operating margin expansion: 9 basis points YoY
    		$79.1 billion3%—$980 million
    Oncology and Multispecialty
    Fueled by strong provider growth, expanded specialty distribution, and contributions from acquisitions.
    Operating profit growth: 53% YoYAcquisitions (PRISM and Core Ventures) contribution to revenue growth: ~13%Organic operating profit growth (excluding acquisitions): 13%
    		$12.7 billion35%—$385 million
    Prescription Technology Solutions
    Driven by higher prescription volumes in third-party logistics and technology services businesses, and higher demand for access solutions.
    Operating profit growth: 13% YoY
    		$1.5 billion12%—$322 million
    Medical Surgical Solutions
    Driven by higher specialty pharmaceutical volumes, partially offset by lower contributions in the ambulatory care channel. Illness season product demand trended below prior year.
    Operating profit decrease: 5% YoY
    		$2.9 billion1%—$271 million

    Operational metrics

    31
    Shareholder returns
    $5.1 billion
    FY26

    Comprised of share repurchases and dividends.

    Capital expenditures
    $745 million
    FY26

    Centered on distribution technology and infrastructure to support future growth.

    Interest expense
    $59 million
    Q4 FY26

    Reflecting higher average loan portfolio balances during the quarter.

    Effective tax rate
    12.1%
    Q4 FY26

    Included net discrete tax benefits of $158 million related to the liquidation of an investment.

    Diluted weighted average shares outstanding
    122.7 milliondeclined 3% YoY
    Q4 FY26

    Reflecting ongoing share repurchase activity.

    Share repurchases
    $2.7 billion
    Q4 FY26

    Included a $2.25 billion accelerated share repurchase program launched in March.

    Dividends
    $101 million
    Q4 FY26

    Paid during the quarter.

    Total share repurchase authorization
    approximately $7.7 billion
    as of April 2026

    Board of Directors approved an additional $5 billion authorization in April 2026.

    Return on Invested Capital (ROIC)
    34%
    FY26

    Highlighting the strength of the operating model and capital allocation strategy.

    Consolidated operating expenses as a percentage of gross profit
    293 basis point improvementvs prior year
    FY26

    Achieved through targeted investments to modernize operations via automation and AI-driven capabilities.

    McKesson Ventures portfolio losses
    $15 million
    Q4 FY26

    Included in corporate expenses.

    Norway business revenue
    $1 billion
    FY26

    Revenue from the divested Norway business, included in FY26 results.

    Norway business operating profit
    $74 million
    FY26

    Operating profit from the divested Norway business, included in FY26 results.

    Equity investment gain (U.S. Oncology network)
    $51 million
    Q2 FY26

    Gain from the sale of an equity investment in market decisions, recognized in Q2 FY26.

    Medical Surgical Solutions enterprise value
    approximately $13 billion
    current

    Implied by Apollo Funds' $1.25 billion strategic minority investment for ~13% interest.

    Medical Surgical Solutions Term Loan A
    $1 billion
    April 2026

    Part of establishing an independent capital structure for the Medical Surgical Solutions business.

    Medical Surgical Solutions Revolving Credit Facility
    $1 billion
    April 2026

    Part of establishing an independent capital structure for the Medical Surgical Solutions business.

    Additional Medical Surgical Solutions Term Loans
    $2.25 billion
    Q1 FY27

    Expected to be issued in the second half of Q1 FY27 to support the separation.

    LIFO credit
    $182 million
    Q4 FY26

    Related to inventory accounting within the North American Pharmaceutical segment.

    Net gains from Norway divestiture
    $480 million
    Q4 FY26

    GAAP-only results related to the divestiture of retail and distribution businesses in Norway.

    Noncash adjustments to redeemable noncontrolling interests
    $122 million
    Q4 FY26

    GAAP-only results from the Core Ventures acquisition in the oncology and multispecialty segment.

    Oncology network provider additions
    570+
    FY26

    Largest net increase since 2010 for the U.S. oncology network.

    PRISM Vision provider increase
    approximately 20%
    past year

    Increase in providers for the retina and ophthalmology platform.

    Biopharma services patients supported
    3.4 million
    annual verification season

    Record number of patients supported in their journey to access medicines.

    Biopharma services patient savings
    approximately $10 billion
    past year

    Savings on brand and specialty medications, majority for non-GLP-1 drugs.

    Biopharma services prescriptions prevented abandonment
    12 million
    past year

    Estimated number of prescriptions prevented from being abandoned due to affordability challenges.

    Biopharma services patient access enabled
    135 million times
    past year

    Number of times patients were enabled to access their medicines.

    Biopharma services pharmacies digitally connected
    50,000+
    current

    Part of a differentiated and scaled network.

    Biopharma services providers digitally connected
    1 million+
    current

    Part of a differentiated and scaled network.

    Biopharma services brands supported
    650+
    current

    Representing most therapeutic areas.

    Ambient scribe technology users
    1,900+
    current

    Providers in the U.S. oncology network using ambient scribe technology.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendsStable
    Pharmacy scripts specialty$14 billionUSD
    Segment revenue operating income—
    Adjusted EPS EBITDA leverage guidance$39.11USD

    Product announcements

    2
    ProductTypeDetails
    Montreal distribution centerlaunch
    Integrated specialty access and affordability solutionslaunch

    Deals & partnerships

    7
    Apollo Fundsminority investment$1.25 billion

    Definitive agreement for a strategic minority investment in Medical Surgical Solutions. Apollo brings deep experience supporting complex carve-outs and public market transactions. Transaction is subject to regulatory approvals and customary closing conditions.

    Core Venturesacquisition

    Added to McKesson's oncology and multi-specialty platforms at the beginning of fiscal 2026, seamlessly onboarded.

    PRISM Visionacquisition

    Added to McKesson's retina and ophthalmology platforms at the beginning of fiscal 2026, seamlessly onboarded.

    Norway businessdivestiture

    Completed exit from Norway in January, continuing disciplined approach to portfolio optimization.

    Cancer Care Northwestacquisition

    Further expanded the U.S. Oncology network footprint with clinic locations across Washington and Idaho in April.

    OKI Clinicacquisition

    Added to the PRISM Vision retina and ophthalmology platform.

    Retina Macula Instituteacquisition

    Added to the PRISM Vision retina and ophthalmology platform in May, extending its footprint beyond the Mid-Atlantic region.

    Risks & headwinds

    3
    Impact of Inflation Reduction Act (IRA) on branded pharmaceutical pricingQ4 FY26 and ongoing

    Reduced Q4 FY26 revenue growth by approximately 3%

    Mitigation: McKesson continues to manage the business with discipline, ensuring appropriate compensation for critical services and positioning for sustained long-term growth.

    Sequential decline in GLP-1 distribution revenuesQ4 FY26

    Declined 4% sequentially in Q4 FY26

    Mitigation: Management anticipates continued category growth in FY27, with quarter-to-quarter variability driven by market dynamics, but no impact on operating profit in Q4 FY26.

    Lower illness season product demandQ4 FY26

    Medical Surgical Solutions operating profit decreased 5% in Q4 FY26

    Mitigation: Demand for illness season products, including vaccines and testing, trended below the prior year, impacting the Medical Surgical Solutions segment.

    Q&A highlights

    7

    Why is the FY27 RxTS revenue growth guidance slower than historical trends, and what are the expectations for GLP-1 growth within the prior authorization business, especially given the sequential decline in GLP-1 distribution revenue?

    The variability in RxTS revenue growth is primarily due to the 3PL component (55% of revenue), which is impacted by timing of product launches and program launches. Despite revenue variability, the operating profit momentum is strong, reflecting high demand for technology services, including access programs for GLP-1s. GLP-1 solutions continue to see strong demand for prior authorization and affordability.

    “If you think about the composition of revenue in that segment, as we've talked about over the last several years, the 3PL component of that business represents roughly 55% of total revenue. And as we've talked about, that business can vary quite significantly from quarter-to-quarter or year-to-year, driven by a number of factors.”

    asked by Allen Lutz · answered by Britt Vitalone

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Portfolio Optimization

    McKesson made significant progress on its strategic portfolio optimization in fiscal 2026. The company advanced the planned separation of its Medical Surgical Solutions segment, putting transition service agreements in place, executing financing transactions, and signing an agreement with Apollo Funds for a $1.25 billion minority investment. Additionally, McKesson completed its exit from Norway in January, fulfilling its commitment to fully exit the European business and streamlining its portfolio.

    02

    Oncology & Multi-specialty Platform Expansion

    The oncology and multi-specialty platform demonstrated strong growth, with the U.S. oncology network adding over 570 providers in fiscal 2026, marking the largest net increase since 2010. This expansion continued with the addition of Cancer Care Northwest and further integration of Core Ventures. The PRISM Vision retina and ophthalmology platform also increased providers by approximately 20% over the past year, extending its footprint with new practices like OKI Clinic and Retina Macula Institute. Technology adoption, such as ambient scribe technology used by over 1,900 providers, is enhancing physician productivity and patient care.

    03

    Biopharma Services and Patient Access Solutions

    McKesson's biopharma services platform achieved its most successful season to date, supporting a record 3.4 million patients with annual verifications. This platform helped patients save approximately $10 billion on branded and specialty medications, prevented an estimated 12 million prescriptions from abandonment, and enabled patient access over 135 million times. The company launched an industry-first integrated specialty access and affordability solution, connecting benefits verification, prior authorization, and affordability support to accelerate time to therapy for high-cost medications.

    04

    North American Distribution and Supply Chain Resilience

    The North American distribution segment focused on operational excellence and resilience. A new state-of-the-art distribution center was launched in Montreal, expanding capacity and featuring AI-powered automation for enhanced precision and performance. AI-driven inventory planning capabilities were implemented across the supply chain, contributing to working capital savings and strong operating cash flow in fiscal 2026. The company successfully navigated significant winter weather disruption🌐s across 20+ states in January, maintaining operations and minimizing customer impact.

    05

    Capital Deployment and Shareholder Returns

    McKesson demonstrated a disciplined and value-creating capital deployment strategy, returning $5.1 billion to shareholders in fiscal 2026 through share repurchases and dividends. The company's strong earnings growth translated into $5.4 billion in free cash flow, with a return on invested capital of 34%. An additional $5 billion share repurchase authorization was approved in April 2026, bringing the total authorization to approximately $7.7 billion, underscoring confidence in the business's durability and growth outlook.

    06

    Leadership Transition and Continuity

    The company announced the planned retirement of CFO Britt Vitalone, who played a critical role in strengthening McKesson's financial foundation and advancing its capital deployment framework. Brian Tyler, CEO, was elected Chairman of the Board, with Dominic Caruso serving as lead independent director, ensuring continued strong independent oversight. Britt Vitalone will support the CFO transition and serve as a strategic advisor, providing continuity during key initiatives like the medical business separation.

    AI-generated summary of the company’s earnings call. Not investment advice.